Skip to main content

Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

In brief

Morning chemoimmunotherapy linked to nearly 10 months longer survival in small-cell lung cancer

In this retrospective study of 107 patients, those whose first four immunotherapy infusions started before the cohort median of 11:54 had median overall survival of 21.2 months, versus 11.4 months for later infusions. Toxicity and response rates were similar, but the single-center findings show an association, not proof that changing treatment time improves survival; prospective testing is needed.

Journal
Oncoimmunology (Q1)
Published
25 September 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Mehmet Haluk Yucel, Maral Martin Mildanoglu, Ebru Engin Delipoyraz, Hakan Ozcelik, Erdem Sunger, Sena Fidan, et al.
PMID
42788839
DOI
10.1080/2162402X.2026.2738262

Why clinicians should know about it

Abstract

Growing evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors across multiple malignancies. However, evidence in extensive-stage small cell lung cancer (ES-SCLC) remains limited to a single East Asian cohort, and independent validation in other populations is lacking. We conducted a retrospective single-center cohort study of 107 patients with ES-SCLC treated with first-line platinum-etoposide plus atezolizumab or durvalumab. The time of day of administration (ToDA) was defined as the median start time of the first four immunotherapy infusions, and patients were categorized according to the cohort median ToDA. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The cohort median ToDA was 11:54. Patients treated before the median ToDA had significantly longer median PFS (9.07 vs. 7.23 months, p = 0.002) and OS (21.17 vs. 11.43 months, p = 0.002) than those treated later. In multivariable Cox regression analysis, later administration remained independently associated with shorter PFS (adjusted HR 1.63, 95% CI 1.03-2.58; p = 0.038) and OS (adjusted HR 1.65, 95% CI 1.00-2.71; p = 0.049), whereas objective response rates, treatment-related toxicity, and immune-related adverse events were comparable between groups. Morning administration of first-line chemoimmunotherapy was associated with significantly longer survival without increased toxicity in patients with ES-SCLC. These findings support growing evidence that circadian timing may influence immune checkpoint inhibitor efficacy and warrant prospective evaluation of treatment timing as a readily modifiable strategy to optimize immunotherapy delivery.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.